10% Stake of Geovax Labs Inc (GOVX) Held by Sabby Management, LLC

Sabby Management, LLC

stated that they own 10% of Geovax Labs Inc (OTCMKTS:GOVX) in a Schedule 13G/A disclosure that was filed with the Securities and Exchange Commission (SEC) on Thursday, January 4th. The investor owns 8,307,476 shares of the stock valued at $490,141. The reporting parties listed on the disclosure included Sabby Healthcare Master Fund, Ltd, Sabby Volatility Warrant Master Fund, Ltd, Sabby Management, LLC and Hal Mintz. The filing is available through Edgar at this hyperlink.

Separately, ValuEngine upgraded shares of Geovax Labs from a “strong sell” rating to a “sell” rating in a research report on Friday, November 10th.

Shares of Geovax Labs Inc (GOVX) remained flat at $$0.06 during midday trading on Thursday. 80,595 shares of the stock traded hands, compared to its average volume of 719,583. The firm has a market capitalization of $4.87, a price-to-earnings ratio of -1.18 and a beta of 0.11. Geovax Labs Inc has a fifty-two week low of $0.02 and a fifty-two week high of $0.10.

Geovax Labs (OTCMKTS:GOVX) last issued its earnings results on Thursday, November 9th. The biotechnology company reported ($0.01) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.01). The business had revenue of $0.25 million during the quarter, compared to analyst estimates of $0.30 million. equities research analysts predict that Geovax Labs Inc will post -0.04 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3125621/10-stake-of-geovax-labs-inc-govx-held-by-sabby-management-llc.html.

Geovax Labs Profile

GeoVax Labs, Inc (GeoVax) is a clinical-stage biotechnology company. The Company is engaged in developing human vaccines against infectious diseases using its modified vaccine Ankara-virus-like particles (MVA-VLP) vaccine platform. The Company’s platform supports in vivo expression of non-infectious virus-like particles (VLPs) from the cells of the person receiving the vaccine.

Receive News & Ratings for Geovax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geovax Labs and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.